We are in a time of transition in oncology. During this period of remarkable innovation in oncology treatments we have substantial improvements in cancer care, but we also have higher health care costs and a growing population of older patients who have a disproportionate risk of developing cancer. Our successes are real, with a 1.5% reduction in cancer mortality in the United States every year for the last decade and a growing population of cancer survivors.1
Click on the PDF icon at the top of this introduction to read the full article.